2 documents found, page 1 of 1
Gadolinium and gadoteric acid exposure induce long-term down-regulation in eryt...
Coimbra, Susana; Rocha, Susana; D. Viana, Sofia; Rebelo, Rute; Rocha-Pereira, Petronila; Valente, Maria João; Catarino, Cristina; Bronze-da-Rocha, ElsaBackground: Gadolinium-based contrast agents (GBCA) differ in their potential to release gadolinium [Gd (III)], known to be toxic. Gadoteric acid (Gd-DOTA) is a macrocyclic GBCA, with a more stable structure. After GBCA exposure, Gd (III) retention in red blood cells (RBC) and kidney has been reported [1,2]. Nephrogenic systemic fibrosis, a severe condition found in renal disease patients exposed to GBCA, is as...
Short-term and long-term effects of gadolinium and gadoteric acid exposure on r...
Coimbra, Susana; Rocha, Susana; D. Viana, Sofia; Rebelo, Rute; Rocha-Pereira, Petronila; Valente, Maria João; Catarino, Cristina; Bronze-da-Rocha, ElsaBackground: There are currently concerns about the safety of gadolinium-based contrast agents (GBCA), as they can release gadolinium [Gd (III)], known to be toxic. Free Gd (III) deposition at different organs, as kidney and liver, has been reported [1,2]. We found that Gd (III) promotes inflammation and fibrosis in proximal tubular cells [3]. GBCA with macrocyclic structure, as gadoteric acid (Gd-DOTA), are con...